8-K Announcements
6Material company update
Feb 12, 2026·SEC
Material company update
Jan 20, 2026·SEC
Material company update
Jan 12, 2026·SEC
Avadel Pharmaceuticals plc(AVDL)Earnings, Financials & Key Ratios
AVDL•NASDAQ
Price updated Apr 24, 2026
AboutAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Show more
- Revenue$169M+504.8%
- EBITDA-$40M+70.8%
- Net Income-$49M+69.5%
- EPS (Diluted)-0.51+74.5%
- Gross Margin90.97%-6.2%
- EBITDA Margin-23.49%+95.2%
- Operating Margin-25.07%+94.9%
- Net Margin-28.87%+95.0%
- ROE-60.44%+87.4%
AVDL Key Insights
Avadel Pharmaceuticals plc (AVDL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 88 (top 12%)
- ✓Strong 5Y sales CAGR of 23.4%
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 18.7% in last year
- ✗Expensive at 27.9x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AVDL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AVDL Price & Volume
Avadel Pharmaceuticals plc (AVDL) stock price & volume — 10-year historical chart
Loading chart...
AVDL Growth Metrics
Avadel Pharmaceuticals plc (AVDL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.6%
5 Years23.35%
3 Years-
TTM79.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM99.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM100.03%
Return on Capital
10 Years-24.76%
5 Years-52.87%
3 Years-78.15%
Last Year-34.86%
AVDL Recent Earnings
Avadel Pharmaceuticals plc (AVDL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (36%)●Beat Revenue 1/12 qtrs (10%)
Q2 2026Latest
Mar 2, 2026Metric
Actual
Est
EPS
$0.05-162.5%
$0.08
Rev
—
$80M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
—
$0.04
Rev
$77M-3.5%
$80M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.10+400.0%
$0.02
Rev
$68M-7.4%
$74M
Q2 2025
May 7, 2025Metric
Actual
Est
EPS
$0.05+28.6%
$0.07
Rev
$53M-9.8%
$58M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.05vs $0.08-162.5% | —vs $80M |
| Q4 2025 | Nov 4, 2025 | —vs $0.04 | $77Mvs $80M-3.5% |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.02+400.0% | $68Mvs $74M-7.4% |
| Q2 2025 | May 7, 2025 | $0.05vs $0.07+28.6% | $53Mvs $58M-9.8% |
Based on last 12 quarters of dataView full earnings history →
AVDL Peer Comparison
Avadel Pharmaceuticals plc (AVDL) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 | |
 AXSM | 12.89B | 250.50 | -68.07 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PGNY | 2.04B | 26.08 | 40.12 | 10.4% | 5.23% | 13.34% | 0.05 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 COLL | 1.09B | 33.54 | 19.39 | 23.62% | 9.41% | 26.74% | 3.12 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 |
Compare AVDL vs Peers
Avadel Pharmaceuticals plc (AVDL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AVDL Income Statement
Avadel Pharmaceuticals plc (AVDL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 150.25M | 172.74M | 103.27M | 59.22M | 22.33M | 0 | 0 | 27.96M | 169.12M | 248.52M |
Revenue Growth % | -13.26% | 14.97% | -40.22% | -42.66% | -62.28% | -100% | - | - | 504.79% | 79.88% |
Cost of Goods Sold | 13.25M | 16.3M | 17.52M | 12.13M | 5.74M | 0 | 0 | 846K | 15.28M | 13.75M |
COGS % of Revenue | 8.82% | 9.44% | 16.96% | 20.48% | 25.71% | - | - | 3.03% | 9.03% | - |
Gross Profit | 137M▲ 0% | 156.44M▲ 14.2% | 85.75M▼ 45.2% | 47.09M▼ 45.1% | 16.59M▼ 64.8% | 0▼ 100.0% | 0▲ 0% | 27.12M▲ 0% | 153.84M▲ 467.3% | 234.76M▲ 0% |
Gross Margin % | 91.18% | 90.56% | 83.04% | 79.52% | 74.29% | - | - | 96.97% | 90.97% | 94.47% |
Gross Profit Growth % | -15.58% | 14.19% | -45.18% | -45.09% | -64.77% | -100% | - | - | 467.32% | - |
Operating Expenses | 92.68M | 96.74M | 146.31M | 71.2M | 10.78M | 85.55M | 98.56M | 164.97M | 196.24M | 230.24M |
OpEx % of Revenue | 61.68% | 56% | 141.68% | 120.24% | 48.25% | - | - | 589.94% | 116.04% | - |
Selling, General & Admin | 44.18M | 58.86M | 100.36M | 30.18M | 32.41M | 68.5M | 74.52M | 151.71M | 181.04M | 190.35M |
SG&A % of Revenue | 29.4% | 34.08% | 97.18% | 50.97% | 145.09% | - | - | 542.52% | 107.05% | - |
Research & Development | 34.61M | 34.22M | 39.33M | 32.92M | 20.44M | 17.1M | 20.7M | 13.26M | 15.2M | 39.89M |
R&D % of Revenue | 23.04% | 19.81% | 38.08% | 55.59% | 91.53% | - | - | 47.42% | 8.99% | - |
Other Operating Expenses | -6.55M | 2.08M | 1.9M | 8.1M | -42.07M | -53K | 3.35M | 0 | 0 | 0 |
Operating Income | -4.96M▲ 0% | 88.3M▲ 1878.4% | -104.93M▼ 218.8% | -24.11M▲ 77.0% | 5.82M▲ 124.1% | -85.55M▼ 1571.1% | -98.56M▼ 15.2% | -137.85M▼ 39.9% | -42.4M▲ 69.2% | 4.52M▲ 0% |
Operating Margin % | -3.3% | 51.12% | -101.6% | -40.72% | 26.04% | - | - | -492.97% | -25.07% | 1.82% |
Operating Income Growth % | -106.95% | 1878.45% | -218.83% | 77.02% | 124.12% | -1571.13% | -15.21% | -39.86% | 69.24% | - |
EBITDA | 9.52M | 93.18M | -97.5M | -21.63M | 7.5M | -84.73M | -97.07M | -136.08M | -39.72M | 8.2M |
EBITDA Margin % | 6.34% | 53.94% | -94.41% | -36.52% | 33.6% | - | - | -486.65% | -23.49% | 3.3% |
EBITDA Growth % | -88.74% | 878.4% | -204.63% | 77.82% | 134.7% | -1228.99% | -14.56% | -40.19% | 70.81% | 113.22% |
D&A (Non-Cash Add-back) | 14.49M | 4.88M | 7.43M | 2.49M | 1.69M | 815K | 1.49M | 1.77M | 2.68M | 3.68M |
EBIT | -8.76M | 61.01M | -102.58M | -26.1M | 7.91M | -83.2M | -99.1M | -150.89M | -38.25M | 6.45M |
Net Interest Income | -963K | -1.05M | -10.62M | -12.48M | -12.99M | -9.94M | -12.34M | -9.89M | -10.83M | -9.71M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 963K | 1.05M | 10.62M | 12.48M | 12.99M | 9.94M | 12.34M | 9.89M | 10.83M | 9.71M |
Other Income/Expense | -4.75M | 3.15M | -8.27M | -14.47M | -10.9M | -7.6M | -12.88M | -22.93M | -6.68M | -7.78M |
Pretax Income | -9.72M▲ 0% | 91.47M▲ 1041.2% | -113.2M▼ 223.8% | -38.58M▲ 65.9% | -5.08M▲ 86.8% | -93.14M▼ 1732.8% | -111.44M▼ 19.6% | -160.78M▼ 44.3% | -49.08M▲ 69.5% | -3.26M▲ 0% |
Pretax Margin % | -6.47% | 52.95% | -109.61% | -65.16% | -22.75% | - | - | -574.96% | -29.02% | -1.31% |
Income Tax | 31.56M | 24.21M | -17.89M | -5.36M | -12.11M | -15.82M | 26.02M | -501K | -247K | -2.98M |
Effective Tax Rate % | -324.74% | 26.47% | 15.81% | 13.88% | 238.29% | 16.98% | -23.35% | 0.31% | 0.5% | 91.46% |
Net Income | -41.28M▲ 0% | 67.25M▲ 262.9% | -95.3M▼ 241.7% | -33.23M▲ 65.1% | 7.03M▲ 121.2% | -77.33M▼ 1200.3% | -137.46M▼ 77.8% | -160.28M▼ 16.6% | -48.83M▲ 69.5% | -278K▲ 0% |
Net Margin % | -27.47% | 38.93% | -92.29% | -56.11% | 31.47% | - | - | -573.17% | -28.87% | -0.11% |
Net Income Growth % | -201.52% | 262.94% | -241.71% | 65.14% | 121.15% | -1200.3% | -77.77% | -16.59% | 69.53% | 99.62% |
Net Income (Continuing) | -41.28M | 68.27M | -95.3M | -33.23M | 7.03M | -77.33M | -137.46M | -160.28M | -48.83M | -278K |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.00▲ 0% | 1.61▲ 261.0% | -2.55▼ 258.4% | -0.89▲ 65.1% | 0.13▲ 114.6% | -1.32▼ 1115.4% | -2.29▼ 73.5% | -2.00▲ 12.7% | -0.51▲ 74.5% | -0.00▲ 0% |
EPS Growth % | -207.53% | 261% | -258.39% | 65.1% | 114.61% | -1115.38% | -73.48% | 12.66% | 74.5% | 100.03% |
EPS (Basic) | -1.00 | 1.66 | -2.55 | -0.89 | 0.13 | -1.32 | -2.29 | -2.00 | -0.51 | - |
Diluted Shares Outstanding | 41.25M | 41.77M | 37.33M | 37.4M | 54.94M | 58.53M | 60.09M | 80.17M | 95.14M | 101.28M |
Basic Shares Outstanding | 41.25M | 40.47M | 37.33M | 37.4M | 53M | 58.53M | 60.09M | 80.17M | 95.14M | 97.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AVDL Balance Sheet
Avadel Pharmaceuticals plc (AVDL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 181.19M | 123.95M | 124.85M | 82.38M | 263.45M | 192.49M | 100.84M | 134.2M | 134.21M | 172.23M |
Cash & Short-Term Investments | 154.19M | 94.08M | 99.92M | 64.16M | 221.4M | 157.22M | 96.5M | 105.11M | 73.78M | 91.58M |
Cash Only | 39.22M | 16.56M | 9.32M | 9.77M | 71.72M | 50.71M | 73.98M | 31.17M | 51.37M | 79.81M |
Short-Term Investments | 114.98M | 77.51M | 90.59M | 54.38M | 149.68M | 106.51M | 22.52M | 73.94M | 22.41M | 11.76M |
Accounts Receivable | 17.84M | 16.51M | 13.91M | 11.97M | 38.78M | 31.54M | 2.25M | 12.1M | 34.1M | 42.44M |
Days Sales Outstanding | 43.34 | 34.88 | 49.17 | 73.81 | 633.81 | - | - | 157.98 | 73.59 | 58.29 |
Inventory | 3.26M | 6.16M | 4.77M | 3.57M | 0 | 0 | 0 | 10.38M | 20.3M | 23.91M |
Days Inventory Outstanding | 89.76 | 137.86 | 99.4 | 107.47 | - | - | - | 4.48K | 484.96 | 584.45 |
Other Current Assets | 2.45M | 128K | 4.11M | 561K | 2.25M | 550K | 573K | 2.23M | 882K | 798K |
Total Non-Current Assets | 64.3M | 128.15M | 65.45M | 69.06M | 48.18M | 54.77M | 31.94M | 30.5M | 30.03M | 27.22M |
Property, Plant & Equipment | 3.32M | 3M | 7.8M | 4.16M | 2.96M | 11.49M | 13.24M | 13.08M | 12.86M | 3.01M |
Fixed Asset Turnover | 45.25x | 57.56x | 13.23x | 14.25x | 7.54x | - | - | 2.14x | 13.16x | 25.79x |
Goodwill | 18.49M | 18.49M | 18.49M | 18.49M | 16.84M | 16.84M | 16.84M | 16.84M | 16.84M | 16.84M |
Intangible Assets | 22.84M | 92.29M | 1.63M | 813K | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.77M | 1.4M | 8.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 7.53M | 9.1M | 5.75M | 16.17M | 10.13M | 2.33M | 1.87M | 579K | 337K | 7.38M |
Total Assets | 245.48M▲ 0% | 252.11M▲ 2.7% | 190.3M▼ 24.5% | 151.44M▼ 20.4% | 311.64M▲ 105.8% | 247.26M▼ 20.7% | 132.78M▼ 46.3% | 164.7M▲ 24.0% | 164.24M▼ 0.3% | 199.45M▲ 0% |
Asset Turnover | 0.61x | 0.69x | 0.54x | 0.39x | 0.07x | - | - | 0.17x | 1.03x | 1.38x |
Asset Growth % | 14.19% | 2.7% | -24.52% | -20.42% | 105.79% | -20.66% | -46.3% | 24.03% | -0.28% | 44.59% |
Total Current Liabilities | 62.42M | 86.18M | 38.38M | 35.98M | 15.11M | 21M | 55.79M | 36.85M | 48.83M | 62.49M |
Accounts Payable | 7.11M | 7.48M | 3.5M | 6.1M | 2.93M | 7.68M | 7.89M | 11.43M | 7.33M | 12.58M |
Days Payables Outstanding | 195.75 | 167.42 | 73 | 183.63 | 186.5 | - | - | 4.93K | 175.08 | 259.67 |
Short-Term Debt | 268K | 111K | 106K | 645K | 474K | 0 | 37.67M | 0 | 0 | 740K |
Deferred Revenue (Current) | 2.22M | 2.01M | 114K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 48.33M | 72.17M | 29.74M | 24.7M | 10M | 3.52M | 1.91M | 11.8M | 21.01M | 40.33M |
Current Ratio | 2.90x | 1.44x | 3.25x | 2.29x | 17.44x | 9.17x | 1.81x | 3.64x | 2.75x | 2.76x |
Quick Ratio | 2.85x | 1.37x | 3.13x | 2.19x | 17.44x | 9.17x | 1.81x | 3.36x | 2.33x | 2.37x |
Cash Conversion Cycle | -62.65 | 5.33 | 75.57 | -2.35 | - | - | - | -296.33 | 383.47 | 383.07 |
Total Non-Current Liabilities | 140.99M | 81.37M | 149.14M | 144.65M | 134.26M | 148.02M | 98.14M | 40.1M | 41.55M | 38.74M |
Long-Term Debt | 547K | 156K | 115.73M | 121.69M | 128.21M | 142.4M | 91.61M | 0 | 0 | 34.83M |
Capital Lease Obligations | 0 | 0 | 0 | 2.32M | 1.84M | 1.71M | 780K | 1.69M | 1.12M | 7.12M |
Deferred Tax Liabilities | 134.26M | 72.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 140.44M | 81M | 33.4M | 20.65M | 4.21M | 3.92M | 5.74M | 38.41M | 40.43M | 2.1M |
Total Liabilities | 203.41M | 167.54M | 187.52M | 180.63M | 149.37M | 169.02M | 153.93M | 76.96M | 90.39M | 101.22M |
Total Debt | 815K | 267K | 115.84M | 124.65M | 130.52M | 145M | 131.02M | 2.62M | 1.7M | 37.38M |
Net Debt | -38.4M | -16.3M | 106.52M | 114.88M | 58.8M | 94.3M | 57.04M | -28.54M | -49.67M | -42.44M |
Debt / Equity | 0.02x | 0.00x | 41.67x | - | 0.80x | 1.85x | - | 0.03x | 0.02x | 0.38x |
Debt / EBITDA | 0.09x | 0.00x | - | - | 17.39x | - | - | - | - | 4.56x |
Net Debt / EBITDA | -4.03x | -0.17x | - | - | 7.84x | - | - | - | - | -5.18x |
Interest Coverage | -5.16x | 83.94x | -9.88x | -1.93x | 0.45x | -8.60x | -7.99x | -13.94x | -3.91x | 0.66x |
Total Equity | 42.07M▲ 0% | 84.56M▲ 101.0% | 2.78M▼ 96.7% | -29.2M▼ 1150.3% | 162.27M▲ 655.7% | 78.24M▼ 51.8% | -21.14M▼ 127.0% | 87.74M▲ 514.9% | 73.85M▼ 15.8% | 98.22M▲ 0% |
Equity Growth % | -38.01% | 101.01% | -96.71% | -1150.32% | 655.72% | -51.78% | -127.02% | 514.94% | -15.83% | 39.28% |
Book Value per Share | 1.02 | 2.02 | 0.07 | -0.78 | 2.95 | 1.34 | -0.35 | 1.09 | 0.78 | 0.97 |
Total Shareholders' Equity | 42.07M | 84.56M | 2.78M | -29.2M | 162.27M | 78.24M | -21.14M | 87.74M | 73.85M | 98.22M |
Common Stock | 414K | 414K | 427K | 429K | 583K | 586K | 628K | 898K | 965K | 972K |
Retained Earnings | -319.8M | -263.7M | -357.99M | -391.21M | -384.19M | -447.76M | -585.22M | -745.5M | -794.33M | -789.56M |
Treasury Stock | 0 | -22.36M | -50M | -50M | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -23.57M | -23.27M | -23.42M | -22.81M | -21.05M | -23.94M | -26.34M | -23.17M | -24.58M | -23.58M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AVDL Cash Flow Statement
Avadel Pharmaceuticals plc (AVDL) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 18.9M | 16.66M | -82.72M | -38.33M | -48.73M | -77.31M | -70.3M | -128.51M | -46.91M | 35.6M |
Operating CF Margin % | 12.58% | 9.65% | -80.1% | -64.72% | -218.21% | - | - | -459.58% | -27.74% | - |
Operating CF Growth % | -77.58% | -11.85% | -596.43% | 53.67% | -27.16% | -58.64% | 9.06% | -82.79% | 63.5% | 807.78% |
Net Income | -41.28M | 67.25M | -95.3M | -33.23M | 7.03M | -77.33M | -137.46M | -160.28M | -48.83M | -278K |
Depreciation & Amortization | 14.49M | 4.88M | 7.43M | 2.49M | 1.69M | 815K | 1.49M | 1.77M | 2.68M | 3.68M |
Stock-Based Compensation | 14.68M | 8.07M | 7.85M | 519K | 3M | 8.87M | 7.01M | 15.81M | 20.39M | 13.64M |
Deferred Taxes | -4M | 3.56M | -19.15M | -6.33M | -7.43M | -15.67M | 26.02M | 0 | 0 | 0 |
Other Non-Cash Items | 33.7M | -69.53M | 28.17M | -4.02M | -44.88M | 2.3M | 8.09M | 17.19M | -828K | 25.4M |
Working Capital Changes | 1.31M | 2.42M | -11.71M | 2.25M | -8.13M | 3.69M | 24.54M | -3M | -20.32M | -6.83M |
Change in Receivables | -10.05M | 3.08M | 3.45M | 1.46M | 10.49M | 2.8M | 30K | -10.22M | -21.99M | -5.47M |
Change in Inventory | 1.83M | -2.9M | 711K | 1.16M | -1.35M | 0 | -30K | -9.53M | -9.22M | -8.06M |
Change in Payables | -434K | 596K | -2.03M | 4.64M | -2.79M | 4.23M | -3.11M | 1.54M | -4.09M | 4.62M |
Cash from Investing | -36.63M | -15.7M | -36.98M | 38.72M | -69.72M | 56.93M | 79.7M | -50.09M | 51.78M | 10.19M |
Capital Expenditures | -1.2M | -53.7M | -20.18M | -29K | -98K | -26K | -716K | 0 | 0 | -191.76K |
CapEx % of Revenue | 0.8% | 31.09% | 19.54% | 0.05% | 0.44% | - | - | - | - | 0.08% |
Acquisitions | 628K | 53.11M | 20M | 0 | 25.5M | 16.5M | -80.41M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -36.06M | -53.11M | -20M | 154K | 0 | 0 | 80.41M | 0 | 0 | -15.69M |
Cash from Financing | -7.95M | -23.32M | 112.66M | -27K | 179.68M | 263K | 14.54M | 135.34M | 15.97M | 5.19M |
Debt Issued (Net) | 0 | 0 | 143.75M | 0 | 0 | 0 | 0 | -38.66M | 0 | 0 |
Equity Issued (Net) | 440K | -1000K | -1000K | 118K | 1000K | 0 | 1000K | 1000K | 1000K | 2.69M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -22.36M | -27.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -8.39M | -1.36M | -4.03M | -145K | 0 | 263K | -10.78M | 27.94M | 6.72M | 815.49K |
Net Change in Cash | -25.85M▲ 0% | -22.65M▲ 12.4% | -7.24M▲ 68.0% | 449K▲ 106.2% | 61.95M▲ 13696.9% | -21.01M▼ 133.9% | 23.27M▲ 210.7% | -42.81M▼ 284.0% | 20.2M▲ 147.2% | 51.23M▲ 0% |
Free Cash Flow | 17.7M▲ 0% | -37.04M▼ 309.3% | -102.89M▼ 177.8% | -38.35M▲ 62.7% | -48.83M▼ 27.3% | -77.34M▼ 58.4% | -71.02M▲ 8.2% | -128.51M▼ 81.0% | -46.91M▲ 63.5% | 35.41M▲ 0% |
FCF Margin % | 11.78% | -21.44% | -99.64% | -64.77% | -218.64% | - | - | -459.58% | -27.74% | 14.25% |
FCF Growth % | -78.59% | -309.27% | -177.79% | 62.72% | -27.32% | -58.37% | 8.17% | -80.95% | 63.5% | 142.76% |
FCF per Share | 0.43 | -0.89 | -2.76 | -1.03 | -0.89 | -1.32 | -1.18 | -1.60 | -0.49 | 0.35 |
FCF Conversion (FCF/Net Income) | -0.46x | 0.25x | 0.87x | 1.15x | -6.93x | 1.00x | 0.51x | 0.80x | 0.96x | -127.36x |
Interest Paid | 788K | 1.05M | 3.36M | 6.47M | 6.47M | 6.47M | 0 | 0 | 0 | 5.84M |
Taxes Paid | 27.18M | 19.14M | 776K | 140K | 0 | 76K | 0 | 0 | 0 | 0 |
AVDL Key Ratios
Avadel Pharmaceuticals plc (AVDL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -75.09% | 106.22% | -218.23% | - | 10.56% | -64.3% | -481.49% | -481.35% | -60.44% | -0.33% |
Return on Invested Capital (ROIC) | -98.15% | 184.12% | -88.64% | -18.55% | 2.84% | -32.6% | -70.93% | -217.45% | -76.28% | 10.39% |
Gross Margin | 91.18% | 90.56% | 83.04% | 79.52% | 74.29% | - | - | 96.97% | 90.97% | 94.47% |
Net Margin | -27.47% | 38.93% | -92.29% | -56.11% | 31.47% | - | - | -573.17% | -28.87% | -0.11% |
Debt / Equity | 0.02x | 0.00x | 41.67x | - | 0.80x | 1.85x | - | 0.03x | 0.02x | 0.38x |
Interest Coverage | -5.16x | 83.94x | -9.88x | -1.93x | 0.45x | -8.60x | -7.99x | -13.94x | -3.91x | 0.66x |
FCF Conversion | -0.46x | 0.25x | 0.87x | 1.15x | -6.93x | 1.00x | 0.51x | 0.80x | 0.96x | -127.36x |
Revenue Growth | -13.26% | 14.97% | -40.22% | -42.66% | -62.28% | -100% | - | - | 504.79% | 79.88% |
Related:AVDL Dividend History·AVDL Revenue History·AVDL Price History·AVDL P/E History·AVDL Financial Ratios·AVDL Institutional Holders
AVDL SEC Filings & Documents
Avadel Pharmaceuticals plc (AVDL) SEC filings — annual & quarterly reports (10-K, 10-Q)
AVDL Frequently Asked Questions
Avadel Pharmaceuticals plc (AVDL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Avadel Pharmaceuticals plc (AVDL) reported $248.5M in revenue for fiscal year 2024. This represents a 4972% increase from $4.9M in 1996.
Avadel Pharmaceuticals plc (AVDL) grew revenue by 504.8% over the past year. This is strong growth.
Avadel Pharmaceuticals plc (AVDL) reported a net loss of $0.3M for fiscal year 2024.
Dividend & Returns
Avadel Pharmaceuticals plc (AVDL) has a return on equity (ROE) of -60.4%. Negative ROE indicates the company is unprofitable.
Avadel Pharmaceuticals plc (AVDL) generated $35.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.